Cofactor Genomics

Cofactor Genomics specializes in predictive immune modeling to enhance precision medicine by addressing existing barriers in the field. The company focuses on advancing the use of multidimensional biomarkers as opposed to single-analyte biomarkers through sophisticated health expression models. Cofactor operates one of the first CAP-certified clinical RNA sequencing laboratories, which facilitates efficient and cost-effective clinical trials for its partners. Leveraging its expertise in molecular biology, informatics, and database management, Cofactor Genomics provides high-quality services tailored to the healthcare and pharmaceutical sectors. This includes the development of diagnostic assays that target oncologic, immunologic, and neurodegenerative diseases, thereby contributing to medical research and improving patient outcomes.

David Messina Ph.D

Co-Founder and COO

1 past transactions

Narus Biotechnologies

Acquisition in 2016
Narus Biotechnologies, founded in 2015 by Raman Talwar and Ryan Bloom, is a U.S.-based company that specializes in the development of novel molecular diagnostics for cancer and neurological diseases. The company utilizes cell-free RNA technology to monitor neurodegeneration and offers biomarker development services. In February 2016, Narus Biotechnologies was acquired by Cofactor Genomics, further advancing its mission to address critical health challenges in the fields of neurology and oncology.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.